FDA panel votes for bivalent COVID-19 shots, debates ‘annual’ schedule

All COVID-19 vaccines should be targeted to the original and dominant strains, an FDA advisory panel said Jan. 26, but members debated whether a new modified vaccine every 12 months is optimal.